{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:43:42Z","timestamp":1791582222433,"version":"4.3.4"},"reference-count":37,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["NIHR154383"],"award-info":[{"award-number":["NIHR154383"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2024,2,6]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fibrotic interstitial lung diseases (fILDs) are a heterogeneous group of lung diseases associated with significant morbidity and mortality. Despite a large increase in the number of clinical trials in the last 10 years, current regulatory-approved management approaches are limited to two therapies that prevent the progression of fibrosis. The drug development pipeline is long and there is an urgent need to accelerate this process. This manuscript introduces the concept and design of an innovative research approach to drug development in fILD: a global Randomised Embedded Multifactorial Adaptive Platform in fILD (REMAP-ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Description of the REMAP-ILD concept and design: the specific terminology, design characteristics (multifactorial, adaptive features, statistical approach), target population, interventions, outcomes, mission and values, and organisational structure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The target population will be adult patients with fILD, and the primary outcome will be a disease progression model incorporating forced vital capacity and mortality over 12 months. Responsive adaptive randomisation, prespecified thresholds for success and futility will be used to assess the effectiveness and safety of interventions. REMAP-ILD embraces the core values of diversity, equity, and inclusion for patients and researchers, and prioritises an open-science approach to data sharing and dissemination of results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By using an innovative and efficient adaptive multi-interventional trial platform design, we aim to accelerate and improve care for patients with fILD. Through worldwide collaboration, novel analytical methodology and pragmatic trial delivery, REMAP-ILD aims to overcome major limitations associated with conventional randomised controlled trial approaches to rapidly improve the care of people living with fILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2023-221148","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T13:20:59Z","timestamp":1709731259000},"page":"788-795","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0784-1331","authenticated-orcid":false,"given":"Leticia","family":"Kawano-Dourado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-4988","authenticated-orcid":false,"given":"Tejaswini","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Rivera-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-5117","authenticated-orcid":false,"given":"Bruno Guedes","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Funke-Chambour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1205-5511","authenticated-orcid":false,"given":"Kerri A","family":"Johannson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-9342","authenticated-orcid":false,"given":"Yet Hong","family":"Khor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney B","family":"Montesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2241-7523","authenticated-orcid":false,"given":"Lucilla","family":"Piccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Prosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Molina-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6047-1670","authenticated-orcid":false,"given":"Jacobo","family":"Sellares Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iazsmin","family":"Bauer-Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujeet","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8054-2293","authenticated-orcid":false,"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8093-7084","authenticated-orcid":false,"given":"Duncan","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wendelberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-547X","authenticated-orcid":false,"given":"Anthony C","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5917-4601","authenticated-orcid":false,"given":"Naftali","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-2119","authenticated-orcid":false,"given":"Gisli","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"2025042101250800000_79.8.788.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2025042101250800000_79.8.788.2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01641-2018","article-title":"Telomere length and genetic variant associations with interstitial lung disease progression and survival","volume":"53","author":"Newton","year":"2019","journal-title":"Eur Respir J"},{"key":"2025042101250800000_79.8.788.3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2213-2600(18)30135-8","article-title":"Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study","volume":"6","author":"Dressen","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025042101250800000_79.8.788.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-214478"},{"key":"2025042101250800000_79.8.788.5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1183\/16000617.0158-2019","article-title":"Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review","volume":"29","author":"Khor","year":"2020","journal-title":"Eur Respir Rev"},{"key":"2025042101250800000_79.8.788.6","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201704-288OC"},{"key":"2025042101250800000_79.8.788.7","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1513\/AnnalsATS.201807-443OC","article-title":"Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases","volume":"16","author":"Adegunsoye","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2025042101250800000_79.8.788.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171315"},{"key":"2025042101250800000_79.8.788.9","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215731"},{"key":"2025042101250800000_79.8.788.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2025042101250800000_79.8.788.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-2032ST"},{"key":"2025042101250800000_79.8.788.12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. an official American Thoracic society clinical practice guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042101250800000_79.8.788.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025042101250800000_79.8.788.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025042101250800000_79.8.788.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025042101250800000_79.8.788.16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025042101250800000_79.8.788.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025042101250800000_79.8.788.18","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2B trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025042101250800000_79.8.788.19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26285"},{"key":"2025042101250800000_79.8.788.20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11616","article-title":"Comparison of Bayesian vs frequentist adaptive trial design in the stroke hyperglycemia insulin network effort trial","volume":"5","author":"Broglio","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025042101250800000_79.8.788.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2316"},{"key":"2025042101250800000_79.8.788.22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4188","article-title":"Precision promise (PrP): an adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC)","volume":"40","author":"Picozzi","year":"2022","journal-title":"JCO"},{"key":"2025042101250800000_79.8.788.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.07.005"},{"key":"2025042101250800000_79.8.788.24","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202003-192SD"},{"key":"2025042101250800000_79.8.788.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0034-3"},{"key":"2025042101250800000_79.8.788.26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.823085","article-title":"Challenges for clinical drug development in pulmonary fibrosis","volume":"13","author":"White","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025042101250800000_79.8.788.27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/picr.PICR_206_19","article-title":"Recruitment and retention of the participants in clinical trials: challenges and solutions","volume":"11","author":"Chaudhari","year":"2020","journal-title":"Perspect Clin Res"},{"key":"2025042101250800000_79.8.788.28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/pst.2015","article-title":"Comparison of response adaptive randomization features in multiarm clinical trials with control","volume":"19","author":"Viele","year":"2020","journal-title":"Pharm Stat"},{"key":"2025042101250800000_79.8.788.29","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515626362"},{"key":"2025042101250800000_79.8.788.30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02163-2022"},{"key":"2025042101250800000_79.8.788.31","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.165"},{"key":"2025042101250800000_79.8.788.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510061"},{"key":"2025042101250800000_79.8.788.33","unstructured":"Services USDoHaH, (FDA) FaDA, Health CfDaR, Research CfBEa . Adaptive designs for medical device clinical studies guidance for industry and food and drug administration staff [FDA]. 2016. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adaptive-designs-medical-device-clinical-studies"},{"key":"2025042101250800000_79.8.788.34","doi-asserted-by":"crossref","first-page":"107092","DOI":"10.1016\/j.cct.2023.107092","article-title":"Diversity, equity, and inclusion in clinical trials: a practical guide from the perspective of a trial sponsor","volume":"126","author":"Versavel","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"2025042101250800000_79.8.788.35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025042101250800000_79.8.788.36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2019-000439","article-title":"The its not JUST idiopathic pulmonary fibrosis study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease","volume":"6","author":"Khan","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2025042101250800000_79.8.788.37","article-title":"The Canadian registry for pulmonary fibrosis: design and rationale of a national pulmonary fibrosis registry","volume":"2016","author":"Ryerson","year":"2016","journal-title":"Can Respir J"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-221148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T04:26:07Z","timestamp":1745209567000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-221148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,7,16]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/thorax-2023-221148"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-221148","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}